Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assess Immunogenicity, Safety & Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix-HepB/Hib-MenAC at 15-24 m & of a Dose of Mencevax ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix-HepB/Hib-MenAC

NCT00136604 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00136604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00136604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assess Immunogenicity, Safety & Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix-HepB/Hib-MenAC at 15-24 m & of a Dose of Mencevax ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix-HepB/Hib-MenAC
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
January 22, 2006
Completion date
April 23, 2006
Enrollment
617 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, diphtheria-tetanus-pertussis-hepatitis b-haemophilus influenzae type b-neisseria meningitidis vaccin, haemophilus influenzae type b, hepatitis b, tetanus, whole cell pertussis